Amlodipine/indapamide/perindopril

Drug Profile

Amlodipine/indapamide/perindopril

Alternative Names: Indapamide/perindopril/amlodipine; Perindopril/indapamide/amlodipine; S06593; Triplixam

Latest Information Update: 15 Mar 2016

Price : $50

At a glance

  • Originator Servier
  • Class Antihypertensives; Dihydropyridines; Indoles; Ischaemic heart disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension

Most Recent Events

  • 01 Sep 2014 Servier completes a phase III trial in Essential hypertension in Russia and Serbia (PO, Pill) (ISRCTN16442558)
  • 13 Mar 2013 Phase-III clinical trials in Essential hypertension in Bulgaria, Czech Republic, Hungary, Poland and Slovakia (PO, Capsule) (EudraCT2012-001658-24)
  • 01 Oct 2012 Phase-III clinical trials in Essential hypertension in Russia and Serbia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top